1;Preface;6 2;Contents;8 3;Part I Clinical Aspects;14 3.1;History of the Israeli Cohort of Laron Syndrome Patients ( 1958- 2009);15 3.2;Early Investigations: Characterizations of the Circulating Growth Hormone;20 3.3;Clinical Evidence of Growth Hormone Resistance in Patients with Laron Syndrome;31 3.4;Diagnosis of Laron Syndrome;36 3.5;Genetic Aspects;38 3.6;Clinical Evaluation;62 3.7;Perinatal Development in Laron Syndrome;67 3.8;Linear Growth Pattern of Untreated Laron Syndrome Patients;71 3.9;Head Shape, Size, and Growth of Untreated Patients with Laron Syndrome;98 3.10;Sexual Development in Patients with Laron Syndrome;108 3.11;Sex Hormone Binding Proteins and Sex Hormones in Untreated and IGF- I Treated Patients with Laron Syndrome;126 3.12;The Adipose Tissue in Patients with Laron Syndrome;131 3.13;Investigations to Determine the Cause of Obesity in Patients with Laron Syndrome;141 3.14;Nonalcoholic Fatty Liver Disease ( Nafld) in Patients with Laron Syndrome;149 3.15;Serum Lipids in Patients with Laron Syndrome;154 3.16;Adiponectin and Leptin in Laron Syndrome;161 3.17;Muscle Force and Endurance in Untreated Adult and IGF- I Treated Children with LaronSyndrome;165 3.18;Bone Mineral Density in Untreated and IGF- I or Alendronate- Treated Patients with Laron Syndrome;169 3.19;Muscle-Bone Relationship in Patients with Laron Syndrome;174 3.20;Imaging Findings in Laron Syndrome;178 3.21;Ocular Findings in Laron Syndrome;203 3.22;Hearing in Patients with Laron Syndrome;211 3.23;The Teeth in Patients with Laron Syndrome;215 3.24;Hair, Skin, and Nails in Patients with Laron Syndrome;220 3.25;Hand, Foot, and Organ Size and Growth in Untreated and IGF- I Treated Patients with Laron Syndrome;228 3.26;Lifelong Serum Growth Hormone Levels in Patients with Laron Syndrome;236 3.27;IGF-I Binding Proteins in Laron Syndrome;241 3.28;Serum Prolactin in Untreated and IGF-I Treated Patients with Laron Syndrome;246 3.29;Thyroid Hormones in Untreated and IGF- I Treated Patients with Laron Syndrome;254 3.30;Insulin Secretion and Carbohydrate Metabolism in Patients with Laron Syndrome: From Hypoglycemia to Diabetes Mellitus;258 3.31;Liver Enzymes in Patients with Laron Syndrome;272 3.32;The Hematopoietic System in Patients with Laron Syndrome;281 3.33;Cardiovascular Aspects in Laron Syndrome Patients;290 3.34;Kidney Functions in Untreated and IGF- I Treated Patients with Laron Syndrome;303 3.35;Sleep and Sleep Disorders in Patients with Laron Syndrome;312 3.36;Neurological Aspects in Laron Syndrome;316 3.37;Orthopedic Problems in Laron Syndrome;318 3.38;Psychological Aspects in Patients with Laron Syndrome;320 3.39;Adjustment and Rehabilitation Problems of Children, Adolescents, and Adults with Laron Syndrome;329 3.40;Laron Syndrome Patients with Congenital IGF- I Deficiency Seem Protected from Malignant Diseases;332 3.41;Lifespan and Mortality of Patients with Laron Syndrome;334 3.42;IGF-I Treatment of Patients with Laron Syndrome;336 3.43;IGF-I Stimulation of Head Growth in Patients with Laron Syndrome;374 3.44;Effects of Long-Term Administration of IGF- I on the Adipose Tissue and Carbohydrate Metabolism in Children with Laron Syndrome;381 3.45;Comparison of the Growth Promoting Response of IGF- I in Children with Laron Syndrome with that of hGH in Children with Isolated GH Deficiency;401 3.46;IGF-I Treatment of Adult Patients with Laron Syndrome;404 3.47;Adverse Effects Encountered During IGF- I Treatment of Patients with Laron Syndrome;410 3.48;Summary of the Clinical History: The Laron Syndrome Clock;416 4;Part II The Growth Hormone Receptor " Null" Mouse or the Laron Mouse;418 4.1;The Laron Mouse;419 4.2;Role of GH/IGF-I Deficiency in Aging;423 4.3;Body Composition, Adipose Tissue, and Energy Balance;431 4.4;Metabolism and Metabolic Regulation;440 4.5;Skeletal Muscle;453 4.6;Cardiac Function in GHR-/- Mice;460 4.7;Bone;467 4.8;GHR Knockout and the CNS;474 4.9;Cancer;479 4.10;Reproduction;490 4.11;Conclusions and Future Studies;496 5;Inde